2025.12.17 消息面上，重庆特种机器人企业七腾机器人有限公司（简称"七腾机器人"）拟通过"协议受让+部分要约 收购"方式，合计斥资超16亿元持有胜通能源最多44.99%股份，成为控股股东。 胜通能源成立于2012年，于2022年登陆A股，主营业务为LNG采购、运输、销售以及原油运输服务。今 年前三季度，公司实现归母净利润4439.4万元，同比增长83.58%。 据公告，本次收购设计了"两步走"组合策略。胜通能源控股股东、实控人等同意将其持有的8464万股股 份（占总股本29.99%）以每股13.28元价格转让给七腾机器人及其一致行动人。同时，七腾机器人方面 拟以上述股份转让完成为前提，向上市公司全体股东发出部分要约收购，收购股份数量为4234万股（占 总股本15%），要约收购价13.28元/股。交易完成后，胜通能源实际控制人将变更为七腾机器人董事 长、法定代表人朱冬。 值得关注的是，七腾机器人创始人、实控人朱冬是一名"85后"，毕业于重庆邮电大学，在校期间就创立 了七腾团队，目前直接持有七腾机器人25.87%股权。 七腾机器人于2010年在重庆成立，专注于特种机器人的设计、研发、生产、销售与服务，核心 ...

作者 |第一财经 揭书宜 12月16日，博纳影业（001330.SZ）跌停，报10.82元/股。12月15日，博纳影业也跌去9.96%。 在此之前，博纳影业因间接参投《阿凡达3》而备受市场关注。而在此前的9个交易日中，博纳影业一直 在上涨。博纳影业在12月14日公告称，公司股票连续3个交易日收盘价格涨幅偏离值累计超20%，构成 交易异常波动。 截至12月16日，据灯塔专业版数据，电影《阿凡达3》预售总票房破4800万元。 2025.12.16 本文字数：776，阅读时长大约2分钟 这已经是博纳影业本月第三次发布股票交易异常波动公告。此前，博纳影业已经在12月2日、3日、4 日，以及12月5日、8日、9日，两次出现连续3个交易日内收盘价格涨幅偏离值累计超过20%。 公司公告显示，博纳影业主营电影、影院、剧集等业务，目前业绩处于亏损状态。2025年前三季度公司 实现营业收入9.72亿元，同比微增1.29%，归属于上市公司股东的净利润亏损11.09亿元，亏损额同比扩 大213.11%。 即使最近股价整体上涨不少，但博纳影业在公告中强调，关注到股吧等投资者交流平台内"《阿凡达 3》"有关话题热度较高。需特别说明的是， ...

招商局中国基金(00133.HK)公布，于2025年11月30日之未经审计每股资产净值为5.538美元(43.11港元)。 本文源自：财华网 ...

招商局中国基金(00133)发布公告，本公司于2025年11月30日的未经审计每股资产净值为5.538美元(43.11 港元)。 ...

智通财经APP讯，招商局中国基金(00133)发布公告，本公司于2025年11月30日的未经审计每股资产净值 为5.538美元(43.11港元)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA MERCHANTS CHINA DIRECT INVESTMENTS LIMITED 招商局中國基金有限公司 (於香港註冊成立之有限公司) （股份代號：133） 本公司於 2025 年 11 月 30 日之未經審計每股資產淨值為 5.538 美元(43.11 港元)。 香港，2025 年 12 月 15 日 於本公告日期，本公司執行董事為王效釘先生及簡家宜女士；非執行董事為周星先 生、姚望女士、柯世鋒先生及鄒傳先生；及獨立非執行董事為曾華光先生、厲放博 士、宮少林博士、 Michael Charles VITERI 先生及朱琦先生。 ...

早盘，影视板块盘初活跃，博纳影业（001330）4连板，北京文化、中国电影、金逸影视、华策影视、幸福蓝海冲高。消息面上，电影《阿凡达3》将于12 月19日在国内上映，由于前剧超高票房和人气，《阿凡达3》未映先火。 | | 影视院线 | | | | --- | --- | --- | --- | | | 1701.00 1.24% | | | | 基金 成分股 | 简况(F10) | | 资金 分析 新闻 | | 名称/代码 | 最新 = | | 涨幅 ◆ 5日涨幅 ◆ ▶ | | 博纳影业 | 12.89 | | +9.98% +50.76% | | 001330 | | | | | 领涨龙头1 4天4板 | 最终涨停 09:32 | | | | 北京文化 | 5.22 | | +4.19% +13.23% | | 000802 | | | | | 领涨龙头3 | | | | | 中国电影 | 18.50 | | +3.58% +4.12% | | 600977 融 | | | | | 领涨龙头2 | | | | | 华策影视 | 7.98 | | +2.05% +8.40% | | 创 300133 融 | ...

Core Viewpoint - After three years of being listed, Shengtong Energy (001331) plans to change its controlling shareholder and actual controller [1][2] Company Overview - Shengtong Energy was established in 2012 and went public on the Shenzhen Stock Exchange in September 2022, focusing on the procurement, transportation, and sales of LNG (liquefied natural gas), as well as transportation services for crude oil and general cargo [4] - As of the end of Q3 2025, the actual controller Wei Jisheng directly held 104 million shares, accounting for 36.97% of the company, with a market value of approximately 1.44 billion yuan [4] Shareholder Information - The top shareholders include Wei Jisheng (36.97%), Longkou Yunxuan Investment Center (9.89%), Longkou Tongyi Investment Center (7.54%), and others [5] - The company has experienced significant fluctuations in performance due to LNG market price volatility, with revenues of 5.157 billion yuan, 4.804 billion yuan, and 5.348 billion yuan from 2022 to 2024, and net profits of 172 million yuan, -39.546 million yuan, and -16.891 million yuan during the same period [5] Recent Performance - In the first three quarters of 2025, Shengtong Energy's performance showed recovery, with revenue increasing by 21.34% to 4.513 billion yuan and net profit rising by 83.58% to 44.394 million yuan [7] - The company sources LNG through domestic market pricing and a five-year long-term agreement known as the "import LNG window one-stop service," which is sensitive to market supply and demand [7] - On December 4, the day before the stock suspension, Shengtong Energy's stock surged by 8.06%, closing at 14.75 yuan per share, with a total market value of 4.163 billion yuan [7]

Core Viewpoint - The company, China Merchants China Fund, has announced an investment of 15 million RMB in Boreas Technology (Shanghai) Co., Ltd. as part of its E-round financing, aiming to enhance its portfolio in the medical sector [1] Group 1: Investment Details - The investment agreement was signed on October 28, 2025, and the funding was completed on November 7, 2025 [1] - The investment amount is 15 million RMB, which is approximately 2.1 million USD [1] Group 2: Company Overview - Boreas Technology, established in November 2011, specializes in brain-machine interface technology and is recognized as a high-tech enterprise in mainland China [1] - The company focuses on the research, development, production, and sales of brain-machine interface systems and related technical services [1] Group 3: Market Applications - Boreas Technology's products are applicable in various fields, including neuroscience, psychology, human factors engineering, kinesiology, and management science [1] - The company's innovations also cater to clinical applications for diagnosing, treating, and rehabilitating neurological diseases, gaining recognition from experts in both domestic and international medical fields [1] Group 4: Strategic Implications - The investment in Boreas Technology is expected to increase the proportion of medical-related projects within the company's investment portfolio, optimizing its overall investment strategy [1]

Core Viewpoint - The company has announced an investment in BoRuiKang Technology (Shanghai) Co., Ltd., focusing on brain-machine interface technology, which is expected to enhance its medical-related project portfolio [1] Group 1: Investment Details - China Merchants China Fund's wholly-owned subsidiary, Shenzhen Tianzheng Investment Co., Ltd., signed a share purchase agreement with BoRuiKang Technology, agreeing to invest 15 million RMB in its E-round financing [1] - The investment was completed on November 7, 2025 [1] Group 2: Company Overview - BoRuiKang Technology, established in November 2011, specializes in the research, development, production, and sales of brain-machine interface systems and related equipment [1] - The company aims to provide comprehensive solutions for innovative research in neuroscience and clinical diagnosis, treatment, and rehabilitation of neurological diseases [1] Group 3: Market Position and Recognition - BoRuiKang Technology has accumulated significant technical reserves and development experience in the brain-machine interface field over the years [1] - Its products are applicable in various research fields, including neuroscience, psychology, human factors engineering, kinesiology, and management, as well as in clinical medicine for diagnosing and treating neurological diseases [1] - The company's research achievements and technical capabilities have been widely recognized by experts in the fields of neural engineering and clinical medicine both domestically and internationally [1] Group 4: Strategic Implications - The investment in BoRuiKang Technology is expected to increase the proportion of medical-related projects within the company's investment portfolio, optimizing its overall investment strategy [1]